PS
RVMD icon

Peter Svennilson’s Revolution Medicines RVMD Stock Holding History

Peter Svennilson’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$278M Hold
7,977,384
– – 22.65% 2
2020
Q2 		$252M Hold
7,977,384
– – 21.06% 2
2020
Q1 		$175M Buy
+7,977,384
New +$221M 22.13% 3

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Peter Svennilson's RVMD Position: Q3 2020 in Review

Peter Svennilson held its Revolution Medicines (RVMD) position steady in Q3 2020 at 7,977,384 shares worth $278M. The position accounts for 22.65% of the portfolio, ranked #2.

Peter Svennilson first reported a position in RVMD in Q1 2020 and has held it in 3 quarters since. 90 funds tracked by Wall St. Rank hold RVMD as of Q3 2020.

  • Peter Svennilson held 7,977,384 shares of Revolution Medicines worth $278M as of Q3 2020.
  • Peter Svennilson left its Revolution Medicines share count unchanged in Q3 2020.
  • Revolution Medicines made up 22.65% of Peter Svennilson's portfolio in Q3 2020, its #2 holding.
  • Peter Svennilson first reported a position in Revolution Medicines in Q1 2020 and has held it in 3 quarters since.
  • 90 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2020.

Based on Peter Svennilson's 13F filing for Q3 2020, filed 4 Nov 2020.